T 2524/12 (Anti-ERBB antibody cancer therapy/GENENTECH) 11-07-2016
Download and more information:
Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
BioGeneriX AG
Teva Pharmaceutical Industries Ltd.
I. An appeal was lodged by the patent proprietor (hereinafter "the appellant") against the decision of the opposition division to revoke the European patent No. 1 282 443.
II. In its statement of grounds of appeal, the appellant requested that the decision under appeal be set aside and that a patent be granted on the basis of the set of claims of either the main request or one of the six auxiliary requests. In a common reply to the statement of grounds of appeal, the respondents (opponents 1 and 2) requested that the appeal be dismissed.
III. In a letter dated 9 June 2016 the appellant stated the following:
"The Proprietor no longer approves the text in which the patent was granted. In addition, we withdraw all of the claim requests in the proceedings".
IV. Subsequently, the oral proceedings which had been summoned to take place on 30 June 2016 were cancelled.
1. Pursuant to Article 113(2) EPC the "European Patent Office shall examine, and decide upon, the European Patent application or the European patent only in the text submitted to it, or agreed, by the applicant or the proprietor of the patent".
2. The appellant has withdrawn all claim requests and no longer approves the text in which the patent was granted (see section III above). It thus follows from the provision cited above that there is no subject-matter upon which the board could decide. In such a situation, where a substantive requirement for allowing the appeal is lacking, the proceedings should, in the board's view, be terminated by a decision ordering the dismissal of the appeal (see for example decisions T 163/99, T 1637/06 and T 784/14).
For these reasons it is decided that:
The appeal is dismissed.